- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dr Reddy’s Hit with Rs 27 Lakh Fine in Mexico
New Delhi: Hyderabad-based pharmaceutical giant, Dr Reddy’s Laboratories, has been fined approximately Rs 27 lakh by Mexico’s regulatory body, COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios).
The penalty, equivalent to MXN 6,51,420, was levied due to non-compliance with Mexico’s guidelines for import filings related to a reference standard for one of the company’s active pharmaceutical ingredients (APIs).
COFEPRIS notified Dr Reddy's of a penalty of MXN 6,51,420 "for deviation from prescribed guidelines in filing intimation of import of a reference standard for one of the company's APIs."
Also Read: Dr Reddy's Laboratories Gets CDSCO Panel Nod for Marketing Approval of Siponimod Tablets
In a regulatory filing, Dr Reddy’s explained that COFEPRIS cited two issues, an incorrect invoice date and a mismatch between the import license details and the reference standard’s name.
"Additionally, the fine was imposed due to an error in the date of the invoice and also name of the reference standard Vs import license, " the filing read.
Established in 1984 and headquartered in Hyderabad, Dr Reddy’s Laboratories is a major player in global pharmaceuticals. The company produces a wide array of generic medications, active pharmaceutical ingredients (APIs), and biosimilars, serving key markets like the United States, India, and Russia, as well as other emerging markets.
Dr Reddy's has a diverse therapeutic portfolio covering oncology, gastrointestinal issues, cardiovascular health, and pain management. With a strong focus on R&D, the company is committed to developing complex generics and innovative drug applications.
COFEPRIS, the Federal Commission for Protection against Health Risks, is Mexico’s regulatory agency responsible for ensuring public health standards across pharmaceuticals, food, environmental safety, and other health-related areas. It oversees drug approvals, monitors compliance with health regulations, and controls the import and export of medical and health-related products in Mexico. COFEPRIS plays a key role in protecting consumers from health risks by enforcing regulations and standards for quality and safety across various sectors.
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751